Changes in the Use of Analogue Insulins in 37 206 Children and Adolescents with Type 1 Diabetes in 275 German and Austrian Centers during the Last Twelve Years

Abstract

Aims: To describe changes in insulin treatment in children and adolescents in Germany/Austria regarding short acting (SA)- and long acting (LA) insulin analogues in different age groups over the last twelve years.

Methods: Use of different insulins and treatment regimens were analysed in 37 206 children and adolescents with the age of 0–20 years from 276 German and Austrian centers that were registered in the DPV-database (Dec. 2007). The group was subdivided into 4 age groups (A: 0–4 years; B:5–9 years;C:10–14 years,D:15–19 years). We further analysed the use of analogues from onset of diabetes.

Results: A significantly increasing percentage of pediatric patients in all age groups with Type 1 Diabetes use analogue insulins. In 2007, 48.5% used SA, 45.8% LA. 87.2% of pumps were running with short acting analogue. Age specific analysis: A: 2000: 9.1%SA, 0.7%LA vs. 2007: 50.0%SA, 10.0%LA; B: 2000:5.6%SA, 1.4%LA vs. 2007: 36.8%SA, 27.5%LA C: 2000:14.3%SA, 3.4%LA vs. 2007: 45.3%SA, 49.1%LA D: 2000:26.3%SA, 3.2%LA vs. 2007: 59.1%SA, 61.9%LA. This increase in usage of analogues was also found at onset of diabetes. Corrected for age, center and diabetes duration HbA1c was significantly lower in the group with regular insulin (8.18±0.047%) than with SA (8.32±0.048%) (p<0.0001) and BMI-SDS was only marginal lower in the group with regular insulin (0.45±0.01 kg/m²) than with SA (0.47±0.15) (p>0.007). Similar differences in HbA1c (8.09±0.05% vs. 8.40±0.05%) and BMI-SDS where seen when NPH was compared with LA respectively. After change to SA the reduction of severe hypoglycemia with (6.1/100 pat.years) and without coma (6.2/100 pat.years) was significant and after change to LA for severe hypoglycemia without coma respectively.

Conclusions: Long-term data for the use of new drugs are sparse. In our analysis patients are followed not under study conditions. Still the higher BMI and HbA1c with either SA or LA usage have to be discussed carefully in the context of increasing use of both, long acting and short acting analogues and possible problems with reimbursement.

Key words

type 1 diabetes mellitus - analogue insulin - children - adolescents - short acting analogue - long acting analogue

References

• 1 Danne T, Aman J, Schober E. et al . A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes.  Diabetes Care. 2003;  26 2359-2364
• 2 Danne T, Rastam J, Odendahl R. et al . Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.  Pediatr Diabetes.. 2007;  8 278-285
• 3 Deeb LC, Holcombe JH, Brunelle R. et al . Insulin lispro lowers postprandial glucose in prepubertal children with diabetes.  Pediatrics. 2001;  108 1175-1179
• 4 Deiss D, Kordonouri O, Hartmann R. et al . Treatment with insulin glargine reduces asymptomatic hypoglycaemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.  Pediatric Diabetes. 2007;  8 157-162
• 5 Deja G, Jarosz-Chobot P, Polanska J. The rate of improvement in metabolic control in children with diabetes mellitus type 1 on insulin glargine depends on age.  Exp Clin Endocrinol Diabetes. 2007;  10
• 6 Ford-Adams ME, Murphy NP, Moore EJ. et al . Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus.  Diabetic Medicine. 2003;  20 656-660
• 7 Gale EAM. The rise of childhood type 1 diabetes in the 20^th century.  Diabetes. 2002;  51 3353-3361
• 8 Gerstl E-M, Rabl W, Rosenbauer J. et al . Metabolic control as reflected by HbA1c in children, adolescents and young adults with type 1 diabetes mellitus: combined longitudinal analysis including 27035 patients from 207 centers in Germany and Austria during the last decade.  Europ J Pediatr. 2008;  167 447-453
• 9 Grabert M, Schweiggert F, Holl RW. A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPV.  Comput Meth Prog Biomed. 2002;  69 115-121
• 10 Holl RW, Grabert M, Sorgo W. et al . Contribution of age, gender and insulin administration to weight gain in subjects with IDDM.  Diabetologie. 1998;  41 542-547
• 11 Holcomb JH, Zalani S, Arora VK. et al . Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.  Clin Ther. 2002;  24 629-638
• 12 Kapellen TM, Heim K, Nietzschmann U. et al . Changes in pediatric diabetes care in a 30-yr period at one institution for pediatric diabetology in Germany.  Pediatr Diabetes. 2002;  3 70-73
• 13 Kapellen TM, Galler A, Kiess W. Insulin Treatment. In: Chiarelli F, Dahl-Jorgensen K, Kiess W, eds. Diabetes in Childhood and Adolescence Basel. Karger Verlag 2005: 122-138
• 14 Kiess W, Gausche R, Keller A. et al . Computer-guided, population-based screening system for growth disorders (CrescNet^®) and on-line generation of normative data for growth and development.  Horm Res. 2001;  56 59-66
• 15 Klinkert C, Bachran R, Heidtmann B. et al . For the DPV-initiative age-specific characteristics of the basal insulin-rate for pediatric patients on CSII.  Exp Clin Endocrinol Diabetes;. , eFirst
• 16 Kromeyer-Hauschild K, Wabitzsch M, Kunze D. Perzentile für den Body-mass-Index für das Kinder- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben.  Monatsschr Kinderheilkd. 2001;  149 807-818
• 17 Murphy NP, Keane S, Ong KK. et al . Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimen.  Diabetes Care. 2003;  26 799-804
• 18 Onkamo P, Vaanenen S, Karvonen M. et al . Worldwide increase in incidence of type 1 diabetes: the analysis of data on published incidence trends.  Diabetologia. 1999;  42 1395-1403
• 19 Plank J, Siebenhofer A, Berghold A. et al . Systematic review and meta-analysis of short acting insulin analogues in pediatric patients with diabetes mellitus.  Arch Int Med. 2005;  165 1337-1344
• 20 Pieber TR, Treichel H-C, Hompesch B. et al . Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy.  Diabetic Medicine. 2007;  24 635-642
• 21 Ratner RE, Hirsch IB, Neifing JL. et al . Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes.  Diabetes Care. 2000;  23 639-643
• 22 Robertson KJ, Schoenle E, Guvec C. et al . Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes.  Diabet Med. 2007;  24 27-34
• 23 Rosenbauer J, Icks A, Giani G. Incidence and prevalence of childhood type 1 diabetes mellitus in Germany – model-based national estimates.  J Pediatr Endocrinol Metab. 2002;  15 1497-1504
• 24 Rutledge KS, Chase P, Klingensmith GJ. et al . Effectiveness of postprandial Humalog in toddlers with diabetes.  Pediatrics. 1997;  100 968-972
• 25 Schober E, Schoenle E, Dyk J Van. et al . Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.  J Pediatr Endocinol Metab. 2002;  15 369-376
• 26 Siebenhofer A, Plank J, Berghold A. et al . Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus.  Cochrane Database Syst Rev. 2006;  (2) CD003287

Correspondence